|
马上注册登录,享用更多感控资源,助你轻松入门。
您需要 登录 才可以下载或查看,没有账号?注册
|
×
Benefits and Harms of CT Screening for Lung Cancer: A Systematic
低剂量电脑断层扫描筛查可能有利于个人增加肺癌的风险,但不确定性存在的潜在危害筛选和一般化的结果。
作者:
Peter B. Bach, MD, MAPP
Joshua N. Mirkin, BA
Thomas K. Oliver, BA
Christopher G. Azzoli, MD
Donald A. Berry, PhD
Otis W. Brawley, MD
Tim Byers, MD, MPH
Graham A. Colditz, MD, DrPH
Michael K. Gould, MD, MS
James R. Jett, MD
Anita L. Sabichi, MD
Rebecca Smith-Bindman, MD
Douglas E. Wood, MD
Amir Qaseem, MD, PhD, MHA
Frank C. Detterbeck, MD
From:JAMA. 2012;307(22):2418-2429
Context Lung cancer is the leading cause of cancer death. Most patients are diagnosed
with advanced disease, resulting in a very low 5-year survival. Screening may
reduce the risk of death from lung cancer.
Objective To conduct a systematic review of the evidence regarding the benefits
and harms of lung cancer screening using low-dose computed tomography (LDCT).
A multisociety collaborative initiative (involving the American Cancer Society, American
College of Chest Physicians, American Society of Clinical Oncology, and National
Comprehensive Cancer Network) was undertaken to create the foundation for development
of an evidence-based clinical guideline.
Data Sources MEDLINE (Ovid: January 1996 to April 2012), EMBASE (Ovid: January
1996 to April 2012), and the Cochrane Library (April 2012).
Study Selection Of 591 citations identified and reviewed, 8 randomized trials and
13 cohort studies of LDCT screening met criteria for inclusion. Primary outcomes were
lung cancer mortality and all-cause mortality, and secondary outcomes included nodule
detection, invasive procedures, follow-up tests, and smoking cessation.
Data Extraction Critical appraisal using predefined criteria was conducted on individual
studies and the overall body of evidence. Differences in data extracted by reviewers
were adjudicated by consensus.
Results Three randomized studies provided evidence on the effect of LDCT screening
on lung cancer mortality, of which the National Lung Screening Trial was the most
informative, demonstrating that among 53 454 participants enrolled, screening resulted
in significantly fewer lung cancer deaths (356 vs 443 deaths; lung cancer−specific
mortality, 274 vs 309 events per 100000 person-years for LDCT and control groups,
respectively; relative risk, 0.80; 95% CI, 0.73-0.93; absolute risk reduction, 0.33%;
P=.004). The other 2 smaller studies showed no such benefit. In terms of potential
harms of LDCT screening, across all trials and cohorts, approximately 20% of individuals
in each round of screening had positive results requiring some degree of followup,
while approximately 1% had lung cancer. There was marked heterogeneity in this
finding and in the frequency of follow-up investigations, biopsies, and percentage of
surgical procedures performed in patients with benign lesions. Major complications in
those with benign conditions were rare.
Conclusion Low-dose computed tomography screening may benefit individuals at
an increased risk for lung cancer, but uncertainty exists about the potential harms of
screening and the generalizability of results.
影响因子:28.9
|
|